Veterinary Services (United States) — NAICS 541940

An investor's primer. NAICS (North American Industry Classification System) 2022 code 541940.

1. Overview

Veterinary Services is the business of medical care for animals — the clinics, animal hospitals, and testing labs where licensed veterinarians examine, vaccinate, medicate, and operate on pets, horses, and livestock. It is a licensed, local, labor-intensive health-care industry that is largely cash-pay, and one of the most quietly consolidated corners of Main Street. Federal data put industry receipts at roughly $62.8 billion in 2022 across about 34,000 establishments employing roughly 475,000 people [1][2].

Why it matters to an investor: demand is structurally growing (more pets, owners willing to spend more on them), most care is paid out of pocket at the point of service rather than negotiated down by insurers, and profitable clinics have proven to be attractive, financeable assets — which is why private equity (PE — investment firms that buy companies using pooled capital and debt) and a family-owned candy giant (Mars) have spent a decade rolling them up.

There are two broad ways to get exposure:

• Public markets — a handful of listed "picks and shovels" companies that sell into every vet clinic (diagnostics, drugs, insurance, software) plus pet retailers building clinic networks. Almost none of the actual clinics trade on an exchange.
• Private markets — the operators themselves, reached through private equity, private credit, direct practice ownership, or veterinary real estate.

The real operating question is not just national demand. It is whether an operator can recruit clinicians, fill appointment capacity, retain clients, control labor and drug costs, and scale without damaging medical autonomy or local trust.

2. What it is and how it's structured

Scope (what NAICS 541940 covers). Establishments of licensed veterinary practitioners providing medicine, dentistry, or surgery for animals, plus veterinary testing laboratories [3]. Operating models include:

• Companion-animal general practice (dogs and cats — the large majority of activity).
• Specialty and emergency hospitals (oncology, orthopedics, critical care).
• Mixed-animal, equine, and food-animal (cattle, swine, poultry) practices.
• Mobile, house-call, and preventive/vaccination clinics.
• Veterinary laboratories and diagnostic services.

What it excludes (adjacent NAICS codes). This industry is medical care only. It does not include:

• 812910 Pet Care (except Veterinary) Services — grooming, boarding, training, sitting, microchipping [3].
• 54171 (Research and Development in the Physical, Engineering, and Life Sciences) — veterinary R&D [3].
• 115210 Support Activities for Animal Production — animal breeding, farriers, boarding horses [3].
• Animal drug and vaccine manufacturing (NAICS 325412, pharmaceutical preparations — e.g., Zoetis, Elanco plants) and distribution (NAICS 424210, drug wholesalers — e.g., Covetrus, Patterson). These companies sell into vet clinics but are not in 541940.

Ownership is murkier than legal form suggests. In the American Veterinary Medical Association (AVMA) owner survey, about 94% of responding practices described themselves as independently owned, and 2022 legal-form data show most practices incorporated (corporations 58.2%, S corporations 20.8%, sole proprietorships 9.9%, partnerships 10.2%) — so a veterinarian-owned practice can still be a corporation; legal form is not the same as ultimate parent [5]. Independent analysts nonetheless estimate that corporate/PE ownership has climbed from roughly 8% of practices around 2011 to a quarter-to-half of general practices, and a clear majority of specialty/emergency practices, by the mid-2020s [25][34]. The industry also remains small-operator-heavy: AVMA data show practices with fewer than 10 employees were 50.5% of the total in 2022, and those with 20 or more employees 19.6% [5].

3. How big it is

Federal statistics for NAICS 541940 (our ground truth). These come from different surveys and vintages and should not be summed into a single figure:

The Small Business Administration (SBA) $10 million figure is a program-classification threshold, not an estimate of average practice revenue [4].

Reading the number, and the undercount caveat. The $62.8 billion federal receipts figure covers everything billed by vet establishments — companion-animal, equine, and food-animal medicine, in-clinic product/pharmacy sales, and lab testing. That is why it runs higher than the consumer-facing "vet care" figure the pet industry reports: the American Pet Products Association (APPA) estimated U.S. households spent roughly $40 billion on veterinary care and product sales at clinics, about a third of total U.S. pet spending of ~$158 billion in 2025 [6]. Third-party market-research estimates of a ~$36–42 billion "U.S. veterinary services market" reflect that narrower, companion-animal consumer-spend scoping [7].

The federal business data modestly undercount the number of operating businesses. County Business Patterns (CBP) counts only employer establishments — it excludes the self-employed, nonemployer businesses, and most government workers — so it does not capture the tail of sole-proprietor mobile, relief (locum), and house-call vets who operate without payroll [1]. Our stats file provides no nonemployer total, so we do not add one. This industry is not government-dominated (public-health and USDA veterinary activity sit in other classifications), so the undercount is a small nonemployer tail, not a hidden public sector. Note too that employment (475,106) counts all clinic staff — veterinarians, technicians, assistants, receptionists — not just doctors; many licensed veterinarians also work outside 541940 in government, academia, and industry [13].

The 2022 national concentration ratios were 22.4% of receipts for the largest 4 firms, 28.2% for the largest 8, 33.2% for the largest 20, and 37.3% for the largest 50 [2]. The Herfindahl-Hirschman Index (HHI, a standard concentration measure) is suppressed in the federal data, so no HHI value is reported [2].

4. The investable universe

There is no large, pure-play, U.S.-listed veterinary-services operator. The clinics that generate the $62.8 billion are owned by private companies and PE funds. Public-market investors therefore mostly buy the ecosystem around the exam table. (Tickers and exchanges appear here because this section is about listed access.)

Public companies (the practical listed exposure):

Distribution and software have consolidated too: Covetrus (distribution/practice software) was taken private in 2022, while Patterson Companies (PDCO) remains a listed animal- and dental-products distributor.

Private owners and platforms (who actually runs the clinics):

Independent, veterinarian-owned practices remain roughly half the market by count and are the usual acquisition targets for these platforms.

Bottom line: to own the operators you generally need private-market access; to own vet services through a brokerage account you own diagnostics, pharma, insurance, or retail-plus-clinics, plus one nano-cap pure play (IVP) and a UK listing (CVSG).

5. How the money works

Vet clinics earn on two revenue streams: professional services (exams, vaccines, surgery, dentistry, imaging, hospitalization, in-house diagnostics, specialty/ER referrals) and product sales (prescription and preventive medications, therapeutic diets, retail). Services are the economic core; product/inventory sales run roughly 10%–26% of practice revenue depending on practice type [5], and Inspire's 2024 clinic mix was about 74% services / 26% products [15]. Products lift revenue per visit but tie up inventory, pharmacy, and working capital.

The defining feature: it's largely cash-pay. Unlike human health care, most veterinary bills are paid out of pocket at the point of service. Pet insurance covers only about 3.9% of U.S. pets (5.5% of dogs, 2.0% of cats), and even then it reimburses the owner rather than negotiating network rates [8]. Clinics therefore set their own prices with no third-party payer clawing them back — a structurally attractive feature, and a big reason vet-service prices have outpaced general inflation for years (Section 9).

Unit economics run on clinician capacity. The binding constraint is doctor time. Operators track visits per veterinarian, appointment fill rate and clinician utilization, average transaction value, the diagnostic "attach rate" per visit, revenue per exam room, revenue per operating hour, labor cost per visit, and client retention. As capacity benchmarks (not profit margins), AVMA's 2025 report put median 2023 gross revenue for companion-animal-exclusive practices at about $616,667 per full-time-equivalent (FTE) veterinarian, $371,500 per exam room, and $502 per operating hour [5]. Major cost categories are veterinarian and technician pay, support labor, rent, drugs and supplies, lab services, equipment, software, insurance, and financing. Our federal file gives no industry-wide margins, so profitability must be judged at the company or practice level.

How the corporate owners make money — the roll-up. PE-backed veterinary services organizations (VSOs) buy individual practices at a multiple of EBITDA (earnings before interest, taxes, depreciation, and amortization — a proxy for cash operating profit) — single practices historically ~6–10x, platforms far higher at the 2021 peak — finance the purchases substantially with debt, then create value three ways: (1) multiple arbitrage — many small clinics bought cheaply are worth more once aggregated into a large, diversified platform; (2) operating synergy — group purchasing, in-house diagnostics/pharmacy, shared administration, centralized recruiting; and (3) organic growth — price and volume gains plus new-site (de novo) builds. Doctors are often retained with cash earn-outs or minority equity to keep them producing after the sale; the principal failure mode is clinician attrition or lost client trust after acquisition.

Where the steadiest margins sit. The most reliable profits are in the "picks and shovels" — diagnostics (in-clinic analyzers plus recurring reference-lab and consumable revenue — IDEXX, Zoetis) — and in specialty/emergency care, which is higher-acuity, higher-ticket, and less price-sensitive than routine visits. Both are prized by consolidators, and specialty/ER is now majority corporate-owned [25][34].

6. What drives demand

• Pet population and ownership. Roughly 94–95 million U.S. households — about seven in ten — own a pet [6]. More pets, more visits.
• "Humanization" and willingness to spend. Owners increasingly treat pets as family and pay for advanced care (oncology, orthopedics, chronic-disease management) once reserved for humans.
• Aging, chronically-managed pets that need more lifetime care, diagnostics, and specialty medicine.
• Insurance growth. Pet insurance is small (~4% penetration) but growing fast — U.S. written premium reached $4.74 billion in 2024 [8][9]. As it spreads, it dampens price sensitivity and lifts spend per visit.
• Employment/structural growth. The U.S. Bureau of Labor Statistics (BLS) projects veterinarian employment to grow 10% from 2024 to 2034 (~3,000 openings a year), and veterinary technologist/technician employment 9% over the same period, citing pet spending, expanded treatment options, and growing/aging pet populations [10][11].
• Affordability ceiling and post-pandemic normalization. Vet care is relatively recession-resistant (people prioritize a sick pet) but not immune. APPA reported that 22% of pet owners spent less in 2025, and clinic visit volumes have softened for several years even as prices rose [6]. The likely result is durable nominal demand with mix risk — essential and preventive care holding up better than elective procedures when budgets tighten.
• Agriculture drives the smaller food-animal/equine segment, tied to livestock economics and rural veterinary access.

7. Regulation

Veterinary medicine is licensed and regulated primarily at the state level, with federal overlays on drugs:

• State practice acts and boards license veterinarians and technicians and set standards of care and advertising rules; requirements vary by state [42].
• Corporate Practice of Veterinary Medicine (CPOM). Some states restrict non-veterinarians or business corporations from owning practices or employing vets; others do not; a middle group permits corporate ownership but requires a licensed veterinarian-manager to oversee medical judgment [35][42]. These rules shape how PE consolidators legally structure ownership, and require state-by-state legal review before assuming a national structure can be replicated everywhere.
• Veterinarian-Client-Patient Relationship (VCPR). The U.S. Food and Drug Administration (FDA) holds that a valid VCPR — required before federally regulated prescription or extralabel animal-drug use — generally cannot be established solely by telemedicine; states may add requirements, and some (e.g., Arizona, California) have recently expanded virtual-VCPR pathways [36][37]. This constrains telemedicine and the pharmacy revenue stream.
• Controlled substances. Any vet who orders, dispenses, or administers controlled drugs must register with the U.S. Drug Enforcement Administration (DEA) and often a state authority [36].
• Antitrust. The Federal Trade Commission (FTC) has repeatedly required divestitures in vet deals despite modest national concentration, because local specialty/ER markets can be tight: Mars/VCA (2017) [38], NVA/Compassion First (2020) [39], and JAB Consumer Partners' ~$1.1B SAGE and ~$1.65B Ethos acquisitions (2022), where it also imposed prior-approval and prior-notice conditions on future specialty/ER deals [40]. The Department of Justice (DOJ) and FTC's 2023 Merger Guidelines explicitly target serial "roll-up" acquisitions and competition for workers [41].

8. Competitive dynamics and consolidation

On paper the industry looks fragmented — the top-4 firms held only 22.4% of revenue and the top-50 just 37.3% in 2022 [2]. But those national ratios understate reality, because (a) veterinary competition is local — a metro's specialty/ER market may have very few options — and (b) consolidation is moving fast.

The dominant force is the roll-up. Mars Veterinary Health is the single largest provider of vet care in the country (~2,500 U.S. clinics under Banfield, VCA, and BluePearl) [23][24], followed by JAB's NVA/Ethos and PE platforms including Mission Pet Health, VetCor, Thrive, and PetVet [26][27][30][31][32]. Corporate ownership of general practices climbed from ~8% to an estimated quarter-to-half in about a decade, and to a clear majority in specialty/ER [25][34].

Scale can deliver better purchasing terms, centralized recruiting and training, shared labs/software/scheduling, referral networks, and capital for equipment and de novo sites; independents keep advantages in local reputation, clinician autonomy, and continuity of care. Newer entrants are attacking from retail and e-commerce: Petco runs vet hospitals and vaccination clinics inside stores [20], Chewy is building an owned clinic network (Chewy Vet Care) via its Modern Animal acquisition [21], and Tractor Supply added mobile community clinics through VIP Petcare [22]. Independent, doctor-owned clinics remain roughly half of practices but are a shrinking, aging-ownership share as retiring vets sell to consolidators.

9. Risks

• Affordability ceiling. Vet-service prices have risen far faster than general inflation — the BLS Consumer Price Index (CPI) for veterinary services has averaged on the order of ~5% annually over the long run and spiked to roughly 9% in 2022–23 — while visit volumes have fallen for several years [6][12]. Pricing power is real but not unlimited.
• Labor and wages. A tight market for veterinarians and technicians has pushed up pay and benefits and can cap growth even when demand exists [10][11]. (The AVMA and AAVMC argue supply is now catching up with no dire long-run shortage expected, though rural and food-animal gaps persist — a genuinely contested point [13][14].)
• Leverage in the PE model. Many roll-ups carry heavy debt; some have shown refinancing and integration stress, and private-credit exposure to VSOs is under growing scrutiny [33].
• Regulatory/antitrust risk. Continued FTC attention to consolidation and state CPOM enforcement could constrain the roll-up playbook and pricing [35][40][41].
• Disruption of revenue mix. Retail/e-commerce pharmacies, diagnostic substitution, and gradual telemedicine liberalization could pressure prices and the pharmacy stream clinics rely on [20][21][36].
• Reputational scrutiny of PE ownership (advocacy, media, regulators) around prices and quality of care.
• A relative strength to weigh against these: minimal third-party reimbursement means far less payer/policy risk than human health care.

10. How to invest, and the outlook

Public-market routes. Because the operators are mostly private, listed exposure means the ecosystem: diagnostics (IDXX), animal-health pharma (ZTS, ELAN), pet insurance (TRUP), retail-plus-clinics (WOOF, CHWY, TSCO), and distributor PDCO [16][17][18][19][20][21][22]. Treat these as a basket of different exposures — a diagnostics business, a drug maker, an insurer, and a retailer have different margin structures and should not be valued as if they were clinics. The only U.S.-listed pure clinic operator, Inspire Veterinary Partners (IVP), is a nano-cap with meaningful going-concern risk and is speculative [15]. For a pure-play at scale, the UK's CVS Group (CVSG) is the closest listed proxy. Several ecosystem names (IDEXX, Zoetis) sold off sharply in 2022–23 after their pandemic-era run and have traded unevenly since [16].

Private-market routes. This is where the operators actually live: PE funds and platforms (JAB, Silver Lake, Shore Capital, TSG/Ares and others), private-credit lending to VSOs, direct practice acquisition or associate buy-in/partnership models, regional roll-ups, mobile and specialty platforms, and veterinary real estate (clinics are often financed on the property separately) [27][30][33]. Diligence should scrutinize normalized owner compensation, clinician retention, appointment availability, exam-room utilization, referral sources, service/pharmacy/lab economics, state ownership rules, lease terms, acquisition add-backs, and leverage — and analyze operating returns and real-estate returns separately.

Outlook (forward-looking judgment). The long-term tailwind is intact: more pets, an owner base willing to spend, still-nascent insurance penetration, an aging pet population, and BLS-projected employment growth [10][11]. Near-term is more mixed — visit volumes are soft against a price ceiling, some leveraged platforms face refinancing pressure, deal multiples have come off the 2021 peak, and antitrust friction on roll-ups has risen. Expect consolidation to continue but at more disciplined prices and with uneven returns; the strongest platforms will be those that expand clinical capacity and retain veterinarians without sacrificing local trust. The plausible eventual event is an initial public offering (IPO) of one of the large private platforms — which would, for the first time, give public investors a direct, at-scale way to own the clinics themselves. Until then, the industry's economics accrue mostly to private owners and to the listed companies that arm them.

---

Sources

1. U.S. Census Bureau, County Business Patterns: 2023, NAICS 541940 (establishments, employment, annual and first-quarter payroll; methodology on employer-only coverage). https://data.census.gov/table/CBP2023.CB2300CBP?codeset=naics~54194
2. U.S. Census Bureau, 2022 Economic Census — Concentration of Largest Firms / Selected Statistics, NAICS 541940 (receipts, firms, CR4/CR8/CR20/CR50; HHI suppressed). https://api.census.gov/data/2022/ecnsize/groups/EC2200SIZECONCEN.html
3. U.S. Census Bureau, 2022 NAICS Definition: 541940 Veterinary Services (definition and cross-references/exclusions). https://www.census.gov/naics/?details=541940&year=2022
4. U.S. Small Business Administration, Table of Size Standards / NAICS data, NAICS 541940 ($10 million), 2023. https://www.sba.gov/document/support-table-size-standards
5. American Veterinary Medical Association (AVMA), Economic State of the Veterinary Profession 2025 (legal form, practice-size distribution, ownership survey, inventory share, per-FTE / per-exam-room / per-hour benchmarks). https://ebusiness.avma.org/files/productdownloads/002_AVMA_SotPReport25_NoPasswordPRO.pdf
6. American Pet Products Association (APPA), U.S. Pet Industry Reaches $158 Billion in 2025 / National Pet Owners Survey (households owning pets; total spend; ~$40B vet care; 22% spent less). https://americanpetproducts.org/news
7. Grand View Research, U.S. Veterinary Services Market Size, Industry Report, 2024 (narrower ~$36–42B market scoping). https://www.grandviewresearch.com/industry-analysis/us-veterinary-services-market-report
8. North American Pet Health Insurance Association (NAPHIA), State of the Industry 2025 (penetration 3.9%; 5.5% dogs / 2.0% cats; ~$4.7B premium). https://naphia.org/news/naphia-news/soi-report-2025/
9. AVMA, US pet insurance industry surpasses $4.7B in 2024, 2025. https://www.avma.org/news/us-pet-insurance-industry-surpasses-4b-2024
10. U.S. Bureau of Labor Statistics, Veterinarians: Occupational Outlook Handbook (10% growth 2024–2034; ~3,000 openings/yr). https://www.bls.gov/ooh/healthcare/veterinarians.htm
11. U.S. Bureau of Labor Statistics, Veterinary Technologists and Technicians: Occupational Outlook Handbook (9% growth 2024–2034). https://www.bls.gov/ooh/healthcare/veterinary-technologists-and-technicians.htm
12. U.S. Bureau of Labor Statistics, Consumer Price Index — Veterinarian Services (long-run ~5%/yr; ~9% in 2022–23), via In2013Dollars. https://www.in2013dollars.com/Veterinarian-services/price-inflation
13. AVMA, U.S. veterinarian numbers and No dire shortage of veterinarians anticipated, 2024. https://www.avma.org/news/no-dire-shortage-veterinarians-anticipated-coming-years
14. Association of American Veterinary Medical Colleges (AAVMC), Demand for and Supply of Veterinarians in the U.S. to 2032, 2024. https://www.aavmc.org/wp-content/uploads/2024/06/Demand-for-and-Supply-of-Veterinarians-in-the-U.S.-to-2032-New.pdf
15. Inspire Veterinary Partners, Inc. (Nasdaq: IVP), Full-Year 2024 results (revenue $16.6M; net loss ~$14M; ~74% services / 26% products), SEC filings. https://www.stocktitan.net/news/IVP/inspire-veterinary-partners-reports-full-year-2024-financial-dkzbwbe975ji.html
16. U.S. News & World Report, Best Pet Stocks to Watch (Zoetis, IDEXX, Elanco, Trupanion scale snapshot; IDEXX market value in the tens of billions), 2024–2025. https://money.usnews.com/investing/articles/best-pet-stocks
17. IDEXX Laboratories (Nasdaq: IDXX), 2025 Form 10-K. https://www.sec.gov/Archives/edgar/data/874716/000087471626000038/idxx-20251231.htm
18. Zoetis (NYSE: ZTS), 2025 Form 10-K. https://www.sec.gov/Archives/edgar/data/1555280/000155528026000011/zts-20251231.htm
19. Trupanion (Nasdaq: TRUP), 2025 Form 10-K. https://www.sec.gov/Archives/edgar/data/1371285/000137128526000018/trup-20251231.htm
20. Petco Health and Wellness Company (Nasdaq: WOOF), Form 10-K (FY ending Jan 31, 2026; ~300 full-service vet hospitals, ~1,600 weekly Vetco clinics). https://www.sec.gov/Archives/edgar/data/1826470/000119312526106114/woof-20260131.htm
21. Chewy (NYSE: CHWY), Chewy to Acquire Modern Animal (29 owned clinics; Chewy Vet Care 18→47 locations), 2026. https://investor.chewy.com/news-and-events/news/news-details/2026/Chewy-to-Acquire-Modern-Animal-Accelerating-Evolution-into-a-Fully-Integrated-Healthcare-Ecosystem/default.aspx
22. Tractor Supply Company (Nasdaq: TSCO), Tractor Supply Acquires VIP Petcare Veterinary Services (SEC exhibit; ~2,700 host locations, 39 states, 1M+ pets/yr), 2026. https://www.sec.gov/Archives/edgar/data/916365/000091636526000046/a5282026tsco-ex991.htm
23. Mars Veterinary Health, Our Companies (Banfield, VCA, BluePearl, AniCura). https://marsveterinary.com/who-we-are/our-companies/
24. Fortune, "Candy maker Mars is the biggest provider of vet care in the country," June 2024 (Mars ~2,500 U.S. clinics; Petco context). https://fortune.com/2024/06/10/mars-candy-snickers-pet-care-vet-clinics-petsmart-private-equity/
25. PE Reveal, The 10 Largest Corporate-Owned Veterinary Chains in the US (footprints; corporate-ownership share), 2024. https://pereveal.substack.com/p/the-10-largest-corporate-owned-veterinary
26. JAB Holding Company / National Veterinary Associates (NVA + Ethos), acquisition and footprint materials. https://www.jabholco.com/documents/6/Press%20release%20NVA%20Acquisition.pdf
27. Mission Pet Health, Southern Veterinary Partners and Mission Veterinary Partners Join Together as Mission Pet Health, 2025. https://missionpethealth.com/2025/07/21/southern-veterinary-partners-and-mission-veterinary-partners-join-together-as-mission-pet-health/
28. Silver Lake, Mission Pet Health (portfolio; PE backing). https://www.silverlake.com/portfolio/mission-pet-health/
29. CARE for Pets, Consolidators Plan Merger — Mission Veterinary Partners and Southern Veterinary Partners (~$8.6B; 840+ locations), 2024. https://www.pets.care/news/2024/09/mission-veterinary-partners-and-southern-veterinary-partners-plan-merger/
30. VetCor, Our Story / Harvest Partners portfolio (~900 hospitals, U.S. and Canada). https://www.vetcor.com/about-us/our-story
31. TSG Consumer Partners, Thrive Pet Healthcare (backing; general/specialty/ER footprint). https://www.tsgconsumer.com/pets/thrive-pet-healthcare
32. PetVet Care Centers, About PetVet Care Centers (420+ hospitals). https://www.petvetcarecenters.com/site/about
33. Octus, Private-Credit Exposure to Veterinary Rollups… VSOs Under Increasing Pressure, 2025. https://octus.com/resources/articles/private-credit-exposure-to-veterinary-rollups-shows-growing-dispersion-vsos-under-increasing-pressure/
34. AmeriVet, An Overview of Private Equity Investment in Veterinary Services, 2024. https://amerivet.com/blog/veterinary-private-equity
35. Mahan Law / Holland & Hart, Non-Veterinarian Veterinary Practice Ownership Laws by State (CPOM), 2024. https://mahanlaw.com/practice-areas/buying-a-veterinary-practice/non-veterinarian-ownership-by-states/
36. American Animal Hospital Association (AAHA), VCPR and The patchwork quilt of state veterinary telehealth laws (DEA/controlled substances; state VCPR/telemedicine), 2024. https://www.aaha.org/vcpr/
37. U.S. Food and Drug Administration (FDA), Veterinarian-Client-Patient Relationships, Prescribing/Dispensing Animal Drugs and Telemedicine. https://www.fda.gov/animal-veterinary/product-safety-information/veterinarian-client-patient-relationships-prescribingdispensing-animal-drugs-and-telemedicine
38. U.S. Federal Trade Commission, Mars Incorporated / VCA Inc. (2017 divestiture order). https://www.ftc.gov/legal-library/browse/cases-proceedings/171-0057-mars-incorporated-vca-inc-matter
39. U.S. Federal Trade Commission, FTC Approves Final Order Imposing Conditions on Compassion-First and National Veterinary Associates, 2020. https://www.ftc.gov/news-events/news/press-releases/2020/04/ftc-approves-final-order-imposing-conditions-veterinary-service-providers-compassion-first-national
40. U.S. Federal Trade Commission, FTC Approves Final Order against JAB Consumer Partners… Rollup of Veterinary Services Clinics (SAGE ~$1.1B, Ethos ~$1.65B; prior-approval/notice), 2022. https://www.ftc.gov/news-events/news/press-releases/2022/10/ftc-approves-final-order-against-jab-consumer-partners-protect-pet-owners-private-equity-firms
41. U.S. Department of Justice, 2023 Merger Guidelines: Overview (serial acquisitions; labor-market competition), 2023. https://www.justice.gov/atr/merger-guidelines/overview
42. American Association of Veterinary State Boards (AAVSB), Practice Act Model, 2026, and AVMA licensing overview. https://www.aavsb.org/wp-content/uploads/2026/03/1_PAM_Model-Documents_2026.pdf